Overcoming Resistance to Dual Innate Immune and MEK Inhibition Downstream of KRAS

Role of YAP/TAZ in mechanotransduction

Dupont, S., Morsut, L., Aragona, M., Enzo, E., Giulitti, S., Cordenonsi, M., Zanconato, F., Le Digabel, J., Forcato, M., Bicciato, S., et al. (2011) · Nature · doi:10.1038/nature10137 · Cited by 5,979 · see citing works

Improved vectors and genome-wide libraries for CRISPR screening

Sanjana, N. E., Shalem, O., & Zhang, F. (2014) · Nature Methods · doi:10.1038/nmeth.3047 · Cited by 5,239 · see citing works

Genome-scale CRISPR-Cas9 knockout screening in human cells

Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234 · see citing works

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229 · see citing works

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1

Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,869 · see citing works

RAS oncogenes: weaving a tumorigenic web

Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789 · see citing works

<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i> -Mutant Lung Adenocarcinoma

Skoulidis, F., Goldberg, M. E., Greenawalt, D. M., Hellmann, M. D., Awad, M. M., Gainor, J. F., Schrock, A. B., Hartmaier, R. J., Trabucco, S. E., Gay, L., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0099 · Cited by 1,641 · cited 1× · see citing works

Genetic and pharmacological disruption of the TEAD–YAP complex suppresses the oncogenic activity of YAP

Liu-Chittenden, Y., Huang, B., Shim, J. S., Chen, Q., Lee, S.-J., Anders, R. A., Liu, J. O., & Pan, D. (2012) · Genes &amp; Development · doi:10.1101/gad.192856.112 · Cited by 1,452 · see citing works

T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer

Tran, E., Robbins, P. F., Lu, Y.-C., Prickett, T. D., Gartner, J. J., Jia, L., Pasetto, A., Zheng, Z., Ray, S., Groh, E. M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609279 · Cited by 1,368 · see citing works

The emerging roles of YAP and TAZ in cancer

Moroishi, T., Hansen, C. G., & Guan, K. (2015) · Nature reviews. Cancer · doi:10.1038/nrc3876 · Cited by 1,156 · see citing works

LKB1 modulates lung cancer differentiation and metastasis

Ji, H., Ramsey, M. R., Hayes, D. N., Fan, C., McNamara, K., Kozlowski, P., Torrice, C., Wu, M. C., Shimamura, T., Perera, S. A., et al. (2007) · Nature · doi:10.1038/nature06030 · Cited by 1,064 · see citing works

Co-occurring Genomic Alterations Define Major Subsets of <i>KRAS</i> -Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities

Skoulidis, F., Byers, L. A., Diao, L., Papadimitrakopoulou, V. A., Tong, P., Izzo, J., Behrens, C., Kadara, H., Parra, E. R., Canales, J. R., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1236 · Cited by 936 · see citing works

The Mechanisms behind the Therapeutic Activity of BET Bromodomain Inhibition

Shi, J., & Vakoc, C. R. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.05.016 · Cited by 881 · see citing works

Dragging ras back in the ring

Stephen, A. G., Esposito, D., Bagni, R. K., & McCormick, F. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.017 · Cited by 795 · see citing works

β-Catenin-Driven Cancers Require a YAP1 Transcriptional Complex for Survival and Tumorigenesis

Rosenbluh, J., Nijhawan, D., Cox, A. G., Li, X., Neal, J. T., Schafer, E. J., Zack, T. I., Wang, X., Tsherniak, A., Schinzel, A. C., et al. (2012) · Cell · doi:10.1016/j.cell.2012.11.026 · Cited by 757 · see citing works

KRAS and YAP1 Converge to Regulate EMT and Tumor Survival

Shao, D. D., Xue, W., Krall, E. B., Bhutkar, A., Piccioni, F., Wang, X., Schinzel, A. C., Sood, S., Rosenbluh, J., Kim, J. W., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.004 · Cited by 744 · see citing works

Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer

Kapoor, A., Yao, W., Ying, H., Hua, S., Liewen, A., Wang, Q., Zhong, Y., Wu, C.-J., Sadanandam, A., Hu, B., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.003 · Cited by 716 · cited 2× · see citing works

STK11/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T-cell activity in the lung tumor microenvironment

Koyama, S., Akbay, E. A., Li, Y. Y., Aref, A. R., Skoulidis, F., Herter-Sprie, G. S., Buczkowski, K. A., Liu, Y., Awad, M. M., Denning, W. L., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1439 · Cited by 640 · see citing works

TCC: an R package for comparing tag count data with robust normalization strategies

Sun, J., Nishiyama, T., Shimizu, K., & Kadota, K. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-219 · Cited by 613 · see citing works

<i>Ex Vivo</i> Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids

Jenkins, R. W., Aref, A. R., Lizotte, P. H., Ivanova, E., Stinson, S., Zhou, C. W., Bowden, M., Deng, J., Liu, H., Miao, D., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0833 · Cited by 594 · see citing works

Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells

Lee, H.-J., Zhuang, G., Cao, Y., Du, P., Kim, H.-J., & Settleman, J. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.019 · Cited by 555 · see citing works

The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies

Lin, L., Sabnis, A. J., Chan, E., Olivas, V., Cade, L., Pazarentzos, E., Asthana, S., Neel, D., Yan, J. J., Lu, X., et al. (2015) · Nature Genetics · doi:10.1038/ng.3218 · Cited by 551 · see citing works

Activation of an IL-6 Inflammatory Loop Mediates Trastuzumab Resistance in HER2 Overexpressing Breast Cancers by Expanding the Cancer Stem Cell Population

Korkaya, H., Kim, G., Davis, A., Malik, F., Henry, N., Ithimakin, S., Quraishi, A. A., Tawakkol, N., D'Angelo, R., Paulson, A. K., et al. (2012) · Molecules and Cells · doi:10.1016/j.molcel.2012.06.014 · Cited by 518 · see citing works

Therapy-induced tumour secretomes promote resistance and tumour progression

Obenauf, A. C., Zou, Y., Ji, A. L., Vanharanta, S., Shu, W., Shi, H., Kong, X., Bosenberg, M., Wiesner, T., Rosen, N. X., et al. (2015) · Nature · doi:10.1038/nature14336 · Cited by 485 · see citing works

A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response

Chen, Z., Cheng, K., Walton, Z., Wang, Y., Ebi, H., Shimamura, T., Liu, Y., Tupper, T., Ouyang, J., Li, J., et al. (2012) · Nature · doi:10.1038/nature10937 · Cited by 446 · cited 14× · see citing works

RalB GTPase-Mediated Activation of the IκB Family Kinase TBK1 Couples Innate Immune Signaling to Tumor Cell Survival

Chien, Y., Kim, S., Bumeister, R., Loo, Y., Kwon, S. W., Johnson, C., Balakireva, M. G., Roméo, Y., Kopelovich, L., Gale, M., et al. (2006) · Cell · doi:10.1016/j.cell.2006.08.034 · Cited by 367 · see citing works

LKB1 loss links serine metabolism to DNA methylation and tumorigenesis

Kottakis, F., Nicolay, B. N., Roumane, A., Karnik, R., Gu, H., Nagle, J. M., Boukhali, M., Hayward, M. C., Li, Y. Y., Chen, T., et al. (2016) · Nature · doi:10.1038/nature20132 · Cited by 348 · see citing works

Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains

Stuhlmiller, T. J., Miller, S. M., Zawistowski, J. S., Nakamura, K., Beltrán, A. S., Duncan, J. S., Angus, S. P., Collins, K. A. L., Granger, D. A., Reuther, R. A., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.037 · Cited by 270 · see citing works

Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy

Στρατικόπουλος, Η., Dendy, M., Szabolcs, M. J., Khaykin, A. J., Lefèbvre, C., Zhou, M., & Parsons, R. E. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.05.006 · Cited by 234 · see citing works

Ral GTPases and cancer: linchpin support of the tumorigenic platform

Bodemann, B. O., & White, M. A. (2008) · Nature reviews. Cancer · doi:10.1038/nrc2296 · Cited by 231 · see citing works

Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers

Ebi, H., Corcoran, R. B., Singh, A., Chen, Z., Song, Y., Lifshits, E., Ryan, D. P., Meyerhardt, J. A., Benes, C., Settleman, J., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57909 · Cited by 210 · see citing works

Inhibition of KRAS -Driven Tumorigenicity by Interruption of an Autocrine Cytokine Circuit

Zhu, Z., Aref, A. R., Cohoon, T. J., Barbie, T. U., Imamura, Y., Yang, S., Moody, S. E., Shen, R. R., Schinzel, A. C., Thai, T. C., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0646 · Cited by 193 · see citing works

Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex

Zawistowski, J. S., Bevill, S. M., Goulet, D. R., Stuhlmiller, T. J., Beltran, A. S., Olivares-Quintero, J. F., Singh, D., Sciaky, N., Parker, J. S., Rashid, N. U., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0653 · Cited by 180 · see citing works

WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors

Anastas, J. N., Kulikauskas, R. M., Tamir, T. Y., Rizos, H., Long, G. V., von Euw, E. M., Yang, P., Chen, H., Haydu, L. E., Toroni, R. A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70156 · Cited by 174 · see citing works

Coordinate Direct Input of Both KRAS and IGF1 Receptor to Activation of PI3 kinase in <i>KRAS</i> -Mutant Lung Cancer

Molina-Arcas, M., Hancock, D. C., Sheridan, C., Kumar, M. S., & Downward, J. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0446 · Cited by 157 · see citing works

Discovery and characterization of small molecules that target the GTPase Ral

Yan, C., Liu, D., Li, L., Wempe, M. F., Guin, S., Khanna, M., Meier, J., Hoffman, B., Owens, C., Wysoczynski, C. L., et al. (2014) · Nature · doi:10.1038/nature13713 · Cited by 150 · see citing works

NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition

García-Rendueles, M. E. R., Ricarte‐Filho, J. C., Untch, B. R., Landa, I., Knauf, J. A., Voza, F. A., Smith, V. E., Ganly, I., Taylor, B. S., Persaud, Y., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0330 · Cited by 137 · see citing works

Autophagy Inhibition Dysregulates TBK1 Signaling and Promotes Pancreatic Inflammation

Yang, S., Imamura, Y., Jenkins, R. W., Cañadas, I., Kitajima, S., Aref, A. R., Brannon, A., Oki, E., Castoreno, A. B., Zhu, Z., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0235 · Cited by 89 · see citing works

Inflammation as a driver and vulnerability of KRAS mediated oncogenesis

Kitajima, S., Thummalapalli, R., & Barbie, D. A. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2016.06.009 · Cited by 83 · see citing works

Failure to Induce Apoptosis via BCL-2 Family Proteins Underlies Lack of Efficacy of Combined MEK and PI3K Inhibitors for KRAS-Mutant Lung Cancers

Hata, A. N., Yeo, A., Faber, A. C., Lifshits, E., Chen, Z., Cheng, K. A., Walton, Z., Sarosiek, K. A., Letai, A., Heist, R. S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3728 · Cited by 74 · see citing works

Oncogene Mimicry as a Mechanism of Primary Resistance to BRAF Inhibitors

Sos, M. L., Levin, R. S., Gordan, J. D., Osés-Prieto, J. A., Webber, J. T., Salt, M. B., Hann, B. C., Burlingame, A. L., McCormick, F. P., Bandyopadhyay, S., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.07.010 · Cited by 73 · see citing works

Selective Targeting of the KRAS G12C Mutant: Kicking KRAS When It’s Down

Hobbs, G. A., Wittinghofer, A., & Der, C. J. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.015 · Cited by 69 · see citing works

Targeting TBK1 Inhibits Migration and Resistance to MEK Inhibitors in Mutant NRAS Melanoma

Vu, H. L., & Aplin, A. E. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0204 · Cited by 59 · see citing works

BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma

Loganathan, S. N., Tang, N., Fleming, J. T., Ma, Y., Guo, Y. P., Borinstein, S. C., Chiang, C. C., & Wang, J. (2016) · Oncotarget · doi:10.18632/oncotarget.9762 · Cited by 51 · see citing works

Loss of TRIM33 causes resistance to BET bromodomain inhibitors through MYC- and TGF-β–dependent mechanisms

Shi, X., Mihaylova, V. T., Kuruvilla, L., Chen, F., Viviano, S., Baldassarre, M., Sperandio, D., Martinez, R., Yue, P., Bates, J. G., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1608319113 · Cited by 44 · see citing works

Targeting Pathways Downstream of KRAS in Lung Adenocarcinoma

Zhu, Z., Golay, H. G., & Barbie, D. A. (2014) · Pharmacogenomics · doi:10.2217/pgs.14.108 · Cited by 38 · see citing works

Undifferentiated State Induced by Rb-p53 Double Inactivation in Mouse Thyroid Neuroendocrine Cells and Embryonic Fibroblasts

Kitajima, S., Kohno, S., Kondoh, A., Sasaki, N., Nishimoto, Y., Li, F., Mohammed, M. S. A., Muranaka, H., Nagatani, N., Suzuki, M., et al. (2015) · Stem Cells · doi:10.1002/stem.1971 · Cited by 24 · see citing works

The Hippo signalling pathway and its implications in human health and diseases

Fu, M., Hu, Y., Lan, T., Guan, K., Luo, T., & Luo, M. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01191-9 · Cited by 767 · see citing works

The current state of the art and future trends in RAS-targeted cancer therapies

Punekar, S. R., Velcheti, V., Neel, B. G., & Wong, K.-K. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00671-9 · Cited by 549 · see citing works

Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer

Kitajima, S., Ivanova, E., Guo, S., Yoshida, R., Campisi, M., Sundararaman, S. K., Tange, S., Mitsuishi, Y., Thai, T. C., Masuda, S., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0689 · Cited by 526 · see citing works

Combining epigenetic drugs with other therapies for solid tumours — past lessons and future promise

Morel, D., Jeffery, D., Aspeslagh, S., Almouzni, G., & Postel-Vinay, S. C. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0267-4 · Cited by 457 · see citing works

YAP/TAZ Signaling and Resistance to Cancer Therapy

Nguyen, C. D. K., & Yi, C. (2019) · Trends in Cancer · doi:10.1016/j.trecan.2019.02.010 · Cited by 437 · see citing works

Targeting RAS–RAF–MEK–ERK signaling pathway in human cancer: Current status in clinical trials

Song, Y., Bi, Z., Liu, Y., Qin, F., Wei, Y., & Wei, X. (2023) · Genes &amp; Diseases · doi:10.1016/j.gendis.2022.05.006 · Cited by 212 · see citing works

Chitosan-based nanoparticle co-delivery of docetaxel and curcumin ameliorates anti-tumor chemoimmunotherapy in lung cancer

Zhu, X., Yu, Z., Feng, L., Deng, L., Fang, Z., Liu, Z., Li, Y., Wu, X., Qin, L., Guo, R., et al. (2021) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2021.118237 · Cited by 163 · see citing works

Control of stem cell renewal and fate by YAP and TAZ

Driskill, J. H., & Pan, D. (2023) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00644-5 · Cited by 165 · see citing works

The role of TBK1 in cancer pathogenesis and anticancer immunity

Runde, A. P., Mack, R. M., Breslin, P., & Zhang, J. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02352-y · Cited by 153 · see citing works

Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges

Xiang, Y., Liu, X., Wang, Y., Zheng, D., Meng, Q., Jiang, L., Yang, S., Zhang, S., Zhang, X., Liu, Y., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1366260 · Cited by 146 · see citing works

TREX1 Inactivation Unleashes Cancer Cell STING–Interferon Signaling and Promotes Antitumor Immunity

Tani, T., Mathsyaraja, H., Campisi, M., Li, Z., Haratani, K., Fahey, C. G., Ota, K., Mahadevan, N. R., Shi, Y., Saito, S., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0700 · Cited by 113 · see citing works

Single-cell resolved imaging reveals intra-tumor heterogeneity in glycolysis, transitions between metabolic states, and their regulatory mechanisms

Kondo, H., Ratcliffe, C. D. H., Hooper, S., Ellis, J., MacRae, J. I., Hennequart, M., Dunsby, C. W., Anderson, K. I., & Sahai, E. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108750 · Cited by 109 · see citing works

MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancer

Kitajima, S., Tani, T., Springer, B. F., Campisi, M., Osaki, T., Haratani, K., Chen, M., Knelson, E. H., Mahadevan, N. R., Ritter, J., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.08.015 · Cited by 107 · see citing works

DDX3X Suppresses the Susceptibility of Hindbrain Lineages to Medulloblastoma

Patmore, D. M., Jassim, A., Nathan, E., Gilbertson, R. J., Tahan, D., Hoffmann, N., Tong, Y., Smith, K. S., Kanneganti, T., Suzuki, H., et al. (2020) · Developmental Cell · doi:10.1016/j.devcel.2020.05.027 · Cited by 71 · see citing works

Recent Therapeutic Approaches to Modulate the Hippo Pathway in Oncology and Regenerative Medicine

Barry, E., Simov, V., Valtingojer, I., & Venier, O. (2021) · Cells · doi:10.3390/cells10102715 · Cited by 71 · see citing works

Tumor-Derived cGAMP Regulates Activation of the Vasculature

Campisi, M., Sundararaman, S. K., Shelton, S. E., Knelson, E. H., Mahadevan, N. R., Yoshida, R., Tani, T., Ivanova, E. V., Cañadas, I., Osaki, T., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02090 · Cited by 62 · see citing works

KRAS/LKB1 and KRAS/TP53 co-mutations create divergent immune signatures in lung adenocarcinomas

Gu, M., Xu, T., & Chang, P. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211006950 · Cited by 61 · see citing works

Targeting metabolic vulnerability in mitochondria conquers MEK inhibitor resistance in KRAS-mutant lung cancer

Feng, J., Lian, Z., Xia, X., Lu, Y., Hu, K., Zhang, Y., Liu, Y., Hu, L., Yuan, K., Sun, Z., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.10.023 · Cited by 61 · see citing works

Cancer immune evasion through KRAS and PD-L1 and potential therapeutic interventions

Watterson, A., & Coelho, M. A. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01063-x · Cited by 58 · see citing works

Matrix stiffening and acquired resistance to chemotherapy: concepts and clinical significance

Darvishi, B., Eisavand, M. R., Majidzadeh‐A, K., & Farahmand, L. (2022) · British Journal of Cancer · doi:10.1038/s41416-021-01680-8 · Cited by 52 · see citing works

Targeting TANK-binding kinase 1 (TBK1) in cancer

Revach, O., Liu, S., & Jenkins, R. W. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1826929 · Cited by 47 · see citing works

MET-Induced CD73 Restrains STING-Mediated Immunogenicity of EGFR-Mutant Lung Cancer

Yoshida, R., Saigí, M., Tani, T., Springer, B. F., Shibata, H., Kitajima, S., Mahadevan, N. R., Campisi, M., Kim, W., Kobayashi, Y., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-0770 · Cited by 47 · see citing works

The Hippo pathway: Organ size control and beyond

Guo, P., Wan, S., & Guan, K. (2024) · Pharmacological Reviews · doi:10.1016/j.pharmr.2024.100031 · Cited by 45 · see citing works

TANK-binding kinase 1 (TBK1): An emerging therapeutic target for drug discovery

Xiang, S., Song, S., Tang, H., Smaill, J. B., Wang, A., Xie, H., & Lu, X. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.05.016 · Cited by 41 · see citing works

Mutant KRAS Mediates circARFGEF2 Biogenesis to Promote Lymphatic Metastasis of Pancreatic Ductal Adenocarcinoma

Kong, Y., Luo, Y., Zheng, S., Yang, J., Zhang, D., Zhao, Y., Zheng, H., An, M., Lin, Y., Ai, L., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-3997 · Cited by 42 · see citing works

An Updated Understanding of the Role of YAP in Driving Oncogenic Responses

Morciano, G., Vezzani, B., Missiroli, S., Boncompagni, C., Pinton, P., & Giorgi, C. (2021) · Cancers · doi:10.3390/cancers13123100 · Cited by 36 · see citing works

Targeting the loss of cGAS / STING signaling in cancer

Sasaki, N., Homme, M., & Kitajima, S. (2023) · Cancer Science · doi:10.1111/cas.15913 · Cited by 33 · see citing works

Role Of Epigenetic Drugs In Sensitizing Cancers To Anticancer Therapies: Emerging Trends And Clinical Advancements

Singh, D., Khan, M. A., & Siddique, H. R. (2023) · Epigenomics · doi:10.2217/epi-2023-0142 · Cited by 34 · see citing works

Multiple roles and context-specific mechanisms underlying YAP and TAZ-mediated resistance to anti-cancer therapy

Reggiani, F., Gobbi, G., Ciarrocchi, A., Ambrosetti, D. C., & Sancisi, V. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188341 · Cited by 32 · see citing works

YAP/TAZ mediates resistance to KRAS inhibitors through inhibiting proapoptosis and activating the SLC7A5/mTOR axis

Yang, W., Zhang, M., Zhang, T.-X., Liu, J.-H., Hao, M.-W., Yan, X., Gao, H., Lei, Q.-Y., Cui, J., & Zhou, X. (2024) · JCI Insight · doi:10.1172/jci.insight.178535 · Cited by 31 · see citing works

Cancer cell-autonomous cGAS-STING response confers drug resistance

Lv, Q.-M., Lei, H.-M., Wang, S., Zhang, K., Tang, Y., Shen, Y. H., Lu, L., Chen, H., & Zhu, L. (2023) · Cell chemical biology · doi:10.1016/j.chembiol.2023.05.005 · Cited by 30 · see citing works

Tumor Milieu Controlled by RB Tumor Suppressor

Kitajima, S., Li, F., & Takahashi, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072450 · Cited by 30 · see citing works

Potent molecular-targeted therapies for advanced esophageal squamous cell carcinoma

Ooki, A., Osumi, H., Chìn, K., Watanabe, M., & Yamaguchi, K. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221138377 · Cited by 28 · see citing works

It’s all downstream from here: RTK/Raf/MEK/ERK pathway resistance mechanisms in glioblastoma

Yakubov, R., Kaloti, R., Persaud, P., McCracken, A., Zadeh, G. M., & Bunda, S. (2025) · Journal of Neuro-Oncology · doi:10.1007/s11060-024-04930-w · Cited by 28 · see citing works

Progresses and Pitfalls of Epigenetics in Solid Tumors Clinical Trials

Rossi, A., Zacchi, F., Reni, A., Rota, M., Palmerio, S., Menis, J., Zivi, A., Milleri, S., & Milella, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111740 · Cited by 26 · see citing works

BET Protein Inhibition Prolongs Cardiac Transplant Survival via Enhanced Myocardial Autophagy

Chen, J., Miao, X., Liu, C., Liu, B., Wu, X., Kong, D., Sun, Q., & Gong, W. (2020) · Transplantation · doi:10.1097/tp.0000000000003319 · Cited by 25 · see citing works

RNA sensing induced by chromosome missegregation augments anti-tumor immunity

Sasaki, N., Homme, M., Murayama, T., Osaki, T., Tenma, T., An, T., Takegami, Y., Tani, T., Gedeon, P. C., Kobayashi, Y., et al. (2024) · Molecular Cell · doi:10.1016/j.molcel.2024.11.025 · Cited by 27 · see citing works

Therapeutic targeting of TANK-binding kinase signaling towards anticancer drug development: Challenges and opportunities

Alam, M., Ansari, M. M., Noor, S., Mohammad, T., Hasan, G. M., Kazim, S. N., & Hassan, M. I. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.03.157 · Cited by 19 · see citing works

The components and regulation of the Hippo pathway and its relationships with the progression and treatment of Non-small cell lung cancer (NSCLC)

Feng, Y., Gan, X., Rong, X., & Han, Q. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03946-0 · Cited by 17 · see citing works

Conquering oncogenic KRAS and its bypass mechanisms

Hou, P., & Wang, Y. (2022) · Theranostics · doi:10.7150/thno.71260 · Cited by 17 · see citing works

Targeting the Heterogeneous Genomic Landscape in Triple-Negative Breast Cancer through Inhibitors of the Transcriptional Machinery

van der Noord, V. E., van de Water, B., & Dévédec, S. E. L. (2022) · Cancers · doi:10.3390/cancers14184353 · Cited by 17 · see citing works

LKB1 inhibits intrahepatic cholangiocarcinoma by repressing the transcriptional activity of the immune checkpoint PD-L1

Liu, Z., Li, S., Zeng, J., Zhou, X., Li, H., Liu, X., Li, F., Jiang, B., Zhao, M., & Ma, T. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118068 · Cited by 12 · see citing works

Pituitary Tumorigenesis—Implications for Management

Vamvoukaki, R., Chrysoulaki, M., Betsi, G., & Xekouki, P. (2023) · Medicina · doi:10.3390/medicina59040812 · Cited by 11 · see citing works

The germline factor DDX4 contributes to the chemoresistance of small cell lung cancer cells

Noyes, C., Kitajima, S., Li, F., Suita, Y., Miriyala, S., Isaac, S., Ahsan, N., Knelson, E. H., Vajdi, A., Tani, T., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-04444-7 · Cited by 10 · see citing works

Long non-coding RNA exploration for mesenchymal stem cell characterisation

Riquier, S., Mathieu, M. N., Bessière, C., Boureux, A., Rufflé, F., Lemaı̂tre, J.-M., Djouad, F., Gilbert, N., & Commes, T. (2021) · BMC Genomics · doi:10.1186/s12864-020-07289-0 · Cited by 9 · see citing works

KRAS G12C inhibition and innate immune targeting

Tani, T., Kitajima, S., Conway, E. B., Knelson, E. H., & Barbie, D. A. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.1902991 · Cited by 9 · see citing works

BMP4 and PHLDA1 are plausible drug-targetable candidate genes for KRAS G12A-, G12D-, and G12V-driven colorectal cancer

Ohnami, S., Maruyama, K., Chen, K., Takahashi, Y., Ohshima, K., Ohshima, K., Shimoda, Y., Sakai, A., Kamada, F., Nakatani, S., et al. (2021) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-021-04172-8 · Cited by 8 · see citing works

Pancreatic cancer driver mutations are targetable through distant alternative RNA splicing dependencies

Kawalerski, R. R., Leach, S. D., & Escobar‐Hoyos, L. F. (2021) · Oncotarget · doi:10.18632/oncotarget.27901 · Cited by 8 · see citing works

Therapeutic targeting of syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers

Theardy, M. S., Takeda, M., Sorokin, A., Chen, S., Yang, Z., Wang, X., Kanikarla, P., Coker, O., Nguyen, P., Wei, Y., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102253 · Cited by 6 · see citing works

Immune-related gene IL17RA as a diagnostic marker in osteoporosis

Deng, Y.-J., Li, Z., Wang, B., Li, J., Ma, J., Xue, X., Tian, X., Liu, Q.-C., Zhang, Y., & Yuan, B. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1219894 · Cited by 6 · see citing works

Cross-Domain Feature Disentanglement for Interpretable Modeling of Tumor Microenvironment Impact on Drug Response

Zhai, J., & Liu, H. (2024) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2024.3387930 · Cited by 6 · see citing works

Targeting TAZ-TEAD in minimal residual disease enhances the duration of targeted therapy in melanoma models

Ott, C. A., Purwin, T. J., Chen, P., Chowdhury, S., Mellor, G. L., Luo, K., Mersky, G. L., Tiago, M., Madden, W. D. B., Varney, S. D., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-64682-7 · Cited by 5 · see citing works

Remodeling the immunosuppressive microenvironment of KARS-LKB1 co-mutant non-small cell lung cancer via targeted PGAM5 siRNA delivery for enhanced immunotherapy

Fan, Y., Li, M., Li, M., Zhu, S., Li, Y., Qin, X., Chang, J., Li, Y., Wu, L., Li, K., et al. (2026) · Materials Today · doi:10.1016/j.mattod.2026.01.001 · Cited by 4 · see citing works

Concurrent genetic and non-genetic resistance mechanisms to KRAS inhibition in colorectal cancer

Alonso, S., Chu, K., Granowsky, E., Saraiba-Rabanales, V., Parsons, M. J., Gunasinghe, H. I., Shia, J., Yaeger, R., & Dow, L. E. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.04.009 · Cited by 8 · see citing works

Suppression of STK11 induces expansion of polymorphonuclear myeloid-derived suppressive cells and activation of immune signaling in breast cancer

Wei, T.-H., Hsieh, C., Loh, Z.-J., Chung, W., Lee, K., Chen, Y., Hsu, H., & Shen, C. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04189-8 · Cited by 3 · see citing works

A review and perspective paper: Ras oncogene gets modest, from kingpin to mere henchman

Camonis, J., Aushev, V. N., Zueva, E., & Zalcman, G. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05449-z · Cited by 3 · see citing works

Stratification of non-small cell lung adenocarcinoma patients with EGFR actionable mutations based on drug-resistant stem cell genes

Xie, X., Li, L., Xie, L., Liu, Z., Zhang, G., Gao, X., Peng, W., Deng, H., Yang, Y., Yang, M., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106584 · Cited by 2 · see citing works

KRAS inhibitors in drug resistance and potential for combination therapy

Rathod, L. S., Sakle, N. S., & Mokale, S. N. (2024) · Tumori Journal · doi:10.1177/03008916241289206 · Cited by 2 · see citing works

KRAS mutations disrupt interactions between CD8+ T cells and antigen-presenting cells in the tumor microenvironment of biliary tract cancer

Terasaki, F., Kumagai, S., Fukuda, A., Tanaka, Y., Irie, T., Ito, S., Yamada, M., Onoe, S., Mizuno, T., Kokuryo, T., et al. (2025) · International Immunology · doi:10.1093/intimm/dxaf065 · Cited by 2 · see citing works

Integration of focal adhesion morphogenesis and polarity by DOCK5 promotes YAP/TAZ-driven drug resistance in TNBC

Vargas, P. P., Arias-García, M., Roumeliotis, T. I., Choudhary, J. S., & Bakal, C. (2025) · Molecular Omics · doi:10.1039/d4mo00154k · Cited by 2 · see citing works

Multiplexed Quantitative Screens of Single Cell Shape and YAP/TAZ Localisation Identify DOCK5 as a Coincident Detector of Polarity and Adhesion During MigrationPreprint

Vargas, P. P., Arias-García, M., Roumeliotis, T. I., Choudhary, J. S., & Bakal, C. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.24.218313 · Cited by 2 · see citing works

A new single-cell level R-index for EGFR-TKI resistance and survival prediction in LUADPreprint

Xie, X., Li, L., Xie, L., Liu, Z., Gao, X., Xia, X., Deng, H., Yang, Y., Yang, M., Chang, L., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.07.30.454426 · Cited by 2 · see citing works

Developmental-status-aware transcriptional decomposition establishes a cell state panorama of human cancers

Luo, Y., & Liang, H. (2024) · Genome Medicine · doi:10.1186/s13073-024-01393-6 · Cited by 1 · see citing works

Active fragment assembly strategy enabling fast discovery of KRAS inhibitors against pancreatic cancer cells

Zhang, P., Kong, L., Meng, X., Chen, Y., Jiao, Y., Su, Z., Song, X., Ding, K., & Xia, G. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118807 · Cited by 1 · see citing works

In the literature: April 2019

Bruxiola, G., Cejalvo, J. M., Gambardella, V., & Cervantes, A. M. R. (2019) · ESMO Open · doi:10.1136/esmoopen-2019-000513

A scRNA-seq Based Prediction Model of EGFR-TKIs Resistance in Patients With Non-Small Cell Lung AdenocarcinomaPreprint

Xie, X., Li, L., Xie, L., Liu, Z., Gao, X., Xia, X., Deng, H., Yang, Y., Yang, M., Chang, L., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3970228

Data from MET-Induced CD73 Restrains STING-Mediated Immunogenicity of EGFR-Mutant Lung Cancer

Yoshida, R., Saigí, M., Tani, T., Springer, B. F., Shibata, H., Kitajima, S., Mahadevan, N. R., Campisi, M., Kim, W., Kobayashi, Y., et al. (2023) · doi:10.1158/0008-5472.c.6514215.v1

Therapeutic targeting of Syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancersPreprint

Takeda, M., Theardy, M. S., Sorokin, A. V., Coker, O., Marie, P. K., Chen, S., Yang, Z., Nguyen, P. T.-M., Wei, Y., Yao, J., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.06.606865

Dipeptidyl Peptidase 4 Restoration Facilitates Antitumor Immunity in KRAS-LKB1–Mutant Lung Cancer

Tenma, T., Yoshida, R., Yanada, H., Nitanai, K., Nagato, T., Oyama, K., Sasaki, N., Homme, M., Mori, C., Ohkuri, T., et al. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-25-0199

Cancers modulate p53 truncal neoantigen display to evade T cell detectionPreprint

Haratani, K., Reinhold, B. B., Duke‐Cohan, J. S., Fahey, C. G., Tan, K., Mallis, R. J., Gusev, A., Kehl, K. L., Luo, J., Holliday, E. L., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.26.690562

PTPN2 inhibition unleashes response to STING agonism in head and neck squamous cell cancer

Li, Z., Fu, C., Sehgal, K., Egloff, A. M., Thai, T. C., Monge, O. A., Chuong, C. L., Senent, Y., Lineberry, M. S., Eschle, B. K., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-72372-1

Design and Synthesis of Novel Isoflavene TANK‐Binding Kinase 1 Inhibitors With Anti‐Inflammatory Activity

Falasca, V., Jayasekara, W. S. N., Nardo, D. D., Wenholz, D. S., Gantier, M. P., & Kumar, N. (2026) · ChemMedChem · doi:10.1002/cmdc.70376

Oncogenic KRAS in Cancer Immunotherapy: From Oncogenic Signaling to Tumor-Immune Ecosystem Regulation

Ashrafizadeh, M., Nabavi, N., & Xu, Y. (2026) · Cancer Biome and Targeted Therapy · doi:10.66505/cbtt.v1i3.36

Therapeutic targeting of ROCK reverses EMT in lung cancer cells by impeding TAZ in Hippo signalling pathway

Ghosh, B., & Ghosh, S. S. (2026) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-026-05699-4

YAP and TAZ orchestrate adaptive resistance to KRAS inhibitors

Mira, A., & Ambrogio, C. (2023) · Nature Cancer · doi:10.1038/s43018-023-00580-5 · Cited by 10 · see citing works

Abstract LB088: Identifying mechanisms of immune suppression in KRAS-inhibitor resistance in NSCLC

Kundu, S. T., Barua, A., Garza, S., Peng, D. H., Fradette, J. J., & Gibbons, D. (2026) · Cancer Research · doi:10.1158/1538-7445.am2026-lb088

Abstract 297: Epigenetic activation of IGF1R signaling promotes resistance to momelotinib and MEK inhibition in KRAS-driven lung cancer

Kitajima, S., Asahina, H., Cavanaugh, J. D., Chen, T., Merlino, A. A., Tran, T. C., Wong, K.-K., & Barbie, D. A. (2016) · Cancer Research · doi:10.1158/1538-7445.am2016-297

Abstract 2049: LKB1 regulates BH3-mimetics vulnerability of KRAS mutant non-small cell lung cancer by alternating mitochondrial apoptotic protein interactions

Li, C., Oh, A., Nangia, V., & Hata, A. N. (2019) · Cancer Research · doi:10.1158/1538-7445.am2019-2049

PDK1 and YAP1/TEAD signaling drive acquired KRAS inhibitor resistance in KRAS-mutant non-small cell lung cancerPreprint

Barua, A., Kundu, S. T., Garza, S., Fradette, J. J., Choudhary, B. S., Peng, D. H., Diao, L., Wang, J., & Gibbons, D. L. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.22.696060